{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T07:14:54Z","timestamp":1794899694652,"version":"4.9.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T00:00:00Z","timestamp":1610323200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T00:00:00Z","timestamp":1610323200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["329015138"],"award-info":[{"award-number":["329015138"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immunosuppression including high-dose calcineurin inhibitors (CNI) is essential after lung transplantation. Dosing is usually guided by therapeutic drug monitoring adjusted to target trough levels of CNIs to keep the balance between over-dose causing severe toxicity and increased risk of infections or under-dose with a risk of graft injury. Adaptation of CNI-based immunosuppression by monitoring of torque teno virus (TTV), a latent nonpathogenic DNA virus, measured in the whole blood in addition to conventional therapeutic drug monitoring may reduce the toxicity of immunosuppression with similar efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods\/design<\/jats:title>\n                    <jats:p>\n                      An open-label, randomized, controlled, parallel-group, multicenter trial in lung transplant recipients will be conducted to investigate the safety and efficacy of immunosuppression guided by TTV monitoring as an add-on to conventional therapeutic drug monitoring. Adult lung transplant recipients 21 to 42\u2009days after transplantation are eligible to participate. Patients (\n                      <jats:italic>N<\/jats:italic>\n                      \u00a0=\u2009144) will be randomized 1:1 to the experimental intervention (arm 1: immunosuppression guided by TTV monitoring in addition to conventional therapeutic drug monitoring of tacrolimus trough levels) and control intervention (arm 2: conventional therapeutic drug monitoring). Outcomes will be assessed 12\u2009months after randomization with the change in glomerular filtration rate as the primary endpoint. Secondary endpoints will be additional measurements of renal function, allograft function, incidence of acute rejections, incidence of chronic lung allograft dysfunction, graft loss, and infections.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The results of this randomized controlled trial may reduce the toxicity of immunosuppression after lung transplantation while maintaining the efficacy of immunosuppression. Study results are transferable to all other solid organ transplantations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/show\/NCT04198506\">NCT04198506<\/jats:ext-link>\n                      . Registered on 12 December 2019\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-020-04985-w","type":"journal-article","created":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T08:28:51Z","timestamp":1610353731000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Viral load-guided immunosuppression after lung transplantation (VIGILung)\u2014study protocol for a randomized controlled trial"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9540-9022","authenticated-orcid":false,"given":"Jens","family":"Gottlieb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Reuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Weide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Schade-Brittinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Hoyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Jaksch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,11]]},"reference":[{"issue":"10","key":"4985_CR1","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s40265-018-0930-6","volume":"78","author":"S Ivulich","year":"2018","unstructured":"Ivulich S, Westall G, Dooley M, Snell G. The evolution of lung transplant immunosuppression. Drugs. 2018;78(10):965\u201382.","journal-title":"Drugs."},{"issue":"10","key":"4985_CR2","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.healun.2013.08.007","volume":"32","author":"RD Yusen","year":"2013","unstructured":"Yusen RD, Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Adult Lung and Heart-Lung Transplant Report--2013; focus theme: age. J Heart Lung Transplant. 2013;32(10):965\u201378.","journal-title":"J Heart Lung Transplant"},{"issue":"3","key":"4985_CR3","doi-asserted-by":"publisher","first-page":"e0122975","DOI":"10.1371\/journal.pone.0122975","volume":"10","author":"I Gorzer","year":"2015","unstructured":"Gorzer I, Jaksch P, Kundi M, Seitz T, Klepetko W, Puchhammer-Stockl E. Pre-transplant plasma torque teno virus load and increase dynamics after lung transplantation. PLoS One. 2015;10(3):e0122975.","journal-title":"PLoS One"},{"issue":"3","key":"4985_CR4","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.healun.2016.10.011","volume":"36","author":"I Gorzer","year":"2017","unstructured":"Gorzer I, Jaksch P, Strassl R, Klepetko W, Puchhammer-Stockl E. Association between plasma torque teno virus level and chronic lung allograft dysfunction after lung transplantation. J Heart Lung Transplant. 2017;36(3):366\u20138.","journal-title":"J Heart Lung Transplant"},{"issue":"12","key":"4985_CR5","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1093\/infdis\/jiy452","volume":"218","author":"P Jaksch","year":"2018","unstructured":"Jaksch P, Kundi M, Gorzer I, Murakozy G, Lambers C, Benazzo A, et al. Torque teno virus as a novel biomarker targeting the efficacy of immunosuppression after lung transplantation. J Infect Dis. 2018;218(12):1922\u20138.","journal-title":"J Infect Dis"},{"issue":"8","key":"4985_CR6","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1097\/TP.0000000000000650","volume":"99","author":"M Ravaioli","year":"2015","unstructured":"Ravaioli M, Neri F, Lazzarotto T, Bertuzzo VR, Di Gioia P, Stacchini G, et al. Immunosuppression modifications based on an immune response assay: results of a randomized, controlled trial. Transplantation. 2015;99(8):1625\u201332.","journal-title":"Transplantation"},{"issue":"5","key":"4985_CR7","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.cell.2013.10.034","volume":"155","author":"I De Vlaminck","year":"2013","unstructured":"De Vlaminck I, Khush KK, Strehl C, Kohli B, Luikart H, Neff NF, et al. Temporal response of the human virome to immunosuppression and antiviral therapy. Cell. 2013;155(5):1178\u201387.","journal-title":"Cell."},{"issue":"6","key":"4985_CR8","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1111\/ajt.15251","volume":"19","author":"J Gottlieb","year":"2019","unstructured":"Gottlieb J, Neurohr C, Muller-Quernheim J, Wirtz H, Sill B, Wilkens H, et al. A randomized trial of everolimus-based quadruple therapy vs standard triple therapy early after lung transplantation. Am J Transplant. 2019;19(6):1759\u201369.","journal-title":"Am J Transplant"},{"issue":"9","key":"4985_CR9","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"issue":"8","key":"4985_CR10","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1111\/ajt.12824","volume":"14","author":"P Jaksch","year":"2014","unstructured":"Jaksch P, Ankersmit J, Scheed A, Kocher A, Murakozy G, Klepetko W, et al. Alemtuzumab in lung transplantation: an open-label, randomized, prospective single center study. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2014;14(8):1839\u201345.","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg"},{"issue":"10","key":"4985_CR11","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.healun.2007.07.027","volume":"26","author":"RR Hachem","year":"2007","unstructured":"Hachem RR, Yusen RD, Chakinala MM, Meyers BF, Lynch JP, Aloush AA, et al. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. J Heart Lung Transplant. 2007;26(10):1012\u20138.","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"4985_CR12","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1128\/JVI.77.4.2418-2425.2003","volume":"77","author":"F Maggi","year":"2003","unstructured":"Maggi F, Pifferi M, Fornai C, Andreoli E, Tempestini E, Vatteroni M, et al. TT virus in the nasal secretions of children with acute respiratory diseases: relations to viremia and disease severity. J Virol. 2003;77(4):2418\u201325.","journal-title":"J Virol"},{"issue":"11","key":"4985_CR13","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1111\/ajt.13835","volume":"16","author":"M Strueber","year":"2016","unstructured":"Strueber M, Warnecke G, Fuge J, Simon AR, Zhang R, Welte T, et al. Everolimus versus mycophenolate mofetil de novo after lung transplantation: a prospective, randomized, open-label trial. Am J Transplant. 2016;16(11):3171\u201380.","journal-title":"Am J Transplant"},{"issue":"6","key":"4985_CR14","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1183\/09031936.00150314","volume":"44","author":"AE Holland","year":"2014","unstructured":"Holland AE, Spruit MA, Troosters T, Puhan MA, Pepin V, Saey D, et al. An official European Respiratory Society\/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J. 2014;44(6):1428\u201346.","journal-title":"Eur Respir J"},{"issue":"2","key":"4985_CR15","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/j.1600-6143.2005.01207.x","volume":"6","author":"A Humar","year":"2006","unstructured":"Humar A, Michaels M, Monitoring AIWGoID. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant. 2006;6(2):262\u201374.","journal-title":"Am J Transplant"},{"issue":"1","key":"4985_CR16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/cid\/ciw668","volume":"64","author":"P Ljungman","year":"2017","unstructured":"Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G, et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 2017;64(1):87\u201391.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"4985_CR17","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.healun.2019.03.009","volume":"38","author":"GM Verleden","year":"2019","unstructured":"Verleden GM, Glanville AR, Lease ED, Fisher AJ, Calabrese F, Corris PA, et al. Chronic lung allograft dysfunction: definition, diagnostic criteria, and approaches to treatment-a consensus report from the pulmonary council of the ISHLT. J Heart Lung Transplant. 2019;38(5):493\u2013503.","journal-title":"J Heart Lung Transplant"},{"issue":"12","key":"4985_CR18","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.healun.2007.10.017","volume":"26","author":"S Stewart","year":"2007","unstructured":"Stewart S, Fishbein MC, Snell GI, Berry GJ, Boehler A, Burke MM, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant. 2007;26(12):1229\u201342.","journal-title":"J Heart Lung Transplant"},{"issue":"7\u20138","key":"4985_CR19","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.clinbiochem.2017.01.008","volume":"50","author":"DA Degen","year":"2017","unstructured":"Degen DA, Janardan J, Barraclough KA, Schneider HG, Barber T, Barton H, et al. Predictive performance of different kidney function estimation equations in lung transplant patients. Clin Biochem. 2017;50(7\u20138):385\u201393.","journal-title":"Clin Biochem"},{"key":"4985_CR20","doi-asserted-by":"publisher","unstructured":"Kayser M, Valtin C, Greer M, Karow B, Fuge J, Gottlieb J. Video consultation during the COVID-19 pandemic: a single center\u2019s experience with lung transplant recipients. Telemed J E Health. 2020. https:\/\/doi.org\/10.1089\/tmj.2020.0170 Online ahead of print.","DOI":"10.1089\/tmj.2020.0170"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-020-04985-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-020-04985-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-020-04985-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T12:09:32Z","timestamp":1610626172000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-020-04985-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,11]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["4985"],"URL":"https:\/\/doi.org\/10.1186\/s13063-020-04985-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-38454\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,11]]},"assertion":[{"value":"20 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study will be conducted in accordance with the protocol, with the current version of the Declaration of Helsinki, ICH-GCP Guideline (International Conference on Harmonization - Good Clinical Practice), and applicable national laws and regulatory requirements.The VIGILung study EudraCT No.: 2019-001770-29Protocol version V03F, dated 05 November 2019 has been approved by the Ethics Committees of the Hannover Medical School, Germany (Nr. 8579_AMG_mono_2019) and the Medical University of Vienna (EK Nr.: 1127\/2020) as well as by the German and Austrian Competent Authorities, Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (Vorlage Nr. 4043539), and Bundesamt f\u00fcr Sicherheit im Gesundheitswesen BASG, reference 12760630 on 29 April 2020.Any substantial amendments to the protocol will be submitted to the EC in accordance with national requirements. Additional study sites may only recruit patients if the sponsor already obtained approval for the site.Written informed consent will be obtained from all participants in the trial before inclusion. The patient information and consent form was approved by the Ethics Committee of the Hannover Medical School and Medical University of Vienna. All patients after lung transplantation are followed in specialized follow-up clinics in participating centers. During the first visit after discharge from the hospital which is as early as 21\u2009days after the surgical procedure, patients will be approached about the trial by transplant pulmonologists who are investigators of the trial. Informed consent of participants will also be obtained by transplant pulmonologists who are also investigators of the trial. Screening of patients will be discussed before the visit during team meetings. Patients have already been informed by newsletters, flyers in the waiting area, and social media. It is estimated to screen 250 patients to include 144 patients from screening procedures from previous trials. Any ancillary planned studies using patient data will be included in further informed consent forms of the trial. At this point, no ancillary studies are planned so far.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The ethical approval and patient information include consent to publish the collected data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare to have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}